Wolverine Asset Management’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-520,184
Closed -$5.17M 2208
2021
Q3
$5.17M Sell
520,184
-544
-0.1% -$5.4K 0.04% 278
2021
Q2
$5.18M Sell
520,728
-9,546
-2% -$96.1K 0.04% 269
2021
Q1
$5.28M Sell
530,274
-28,426
-5% -$303K 0.04% 235
2020
Q4
$6.03M Buy
558,700
+86,398
+18% +$889K 0.04% 237
2020
Q3
$4.9M Buy
472,302
+395,577
+516% +$4.11M 0.04% 228
2020
Q2
$771K Buy
+76,725
New +$763K 0.01% 608

Other funds holding STLN

Wolverine Asset Management's STLN Position: Q4 2021 in Review

Wolverine Asset Management sold out of Starling Oncology (STLN) in Q4 2021, closing a stake of 520,184 shares — an estimated $5.17M sold.

Wolverine Asset Management first reported a position in STLN in Q2 2020 and held it in 6 quarters. The position peaked at $6.03M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

  • Wolverine Asset Management reported no remaining Starling Oncology position as of Q4 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 520,184 Starling Oncology shares in Q4 2021, an estimated $5.17M.
  • Wolverine Asset Management first reported a position in Starling Oncology in Q2 2020 and held it in 6 quarters.
  • Wolverine Asset Management's Starling Oncology position peaked at $6.03M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2021.

Based on Wolverine Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.